Emmaus Life Sciences Inc. has appointed Willis C. Lee as Chief Executive Officer (CEO). 

Lee, who previously served as Co-President and Chief Operating Officer, will continue to serve as Chairman of the Board.

Lee said, “We are working hard to improve the efficiency of the company by reorganizing every level of our operations. We believe that these moves will better position us to serve our patients, clients, and shareholders, and equip us to face the challenges posed by the launch of generic L-glutamine.  As the new CEO, I will ensure that we continue to grow our market presence in the Middle East and invest in research that will expand our pipelines and increase the value of the company. In the next few months, I will work aggressively with the Board, members of the newly restructured teams, and all stakeholders to ensure that your trust in us is well justified.”

This news comes weeks after Emmaus received the “No Action Indicated” classification following an inspection by the FDA of Emmaus’ Postmarketing Adverse Drug Experience (PADE) compliance program.